» Articles » PMID: 35608859

Transmission and Infectious SARS-CoV-2 Shedding Kinetics in Vaccinated and Unvaccinated Individuals

Overview
Journal JAMA Netw Open
Specialty General Medicine
Date 2022 May 24
PMID 35608859
Authors
Affiliations
Soon will be listed here.
Abstract

Importance: Data are limited on whether patients with breakthrough COVID-19 infection have the potential to significantly contribute to the spread of SARS-CoV-2.

Objective: To compare the secondary attack rate and infectious viral shedding kinetics of SARS-CoV-2 between fully vaccinated individuals (breakthrough infection group) and partially or unvaccinated individuals (nonbreakthrough infection group).

Design, Setting, And Participants: This cohort study assessed secondary transmission by analyzing the epidemiologic data of health care workers, inpatients, and caregivers diagnosed with COVID-19 during hospitalization or residence in a tertiary care hospital between March 1, 2020, and November 6, 2021. To evaluate viral shedding kinetics, the genomic RNA of SARS-CoV-2 was measured using polymerase chain reaction and performed virus culture from daily saliva samples of individuals with mild COVID-19 infected with the Delta variant who were isolated in a community facility in Seoul, South Korea, between July 20 and August 20, 2021.

Exposures: COVID-19 vaccination.

Main Outcomes And Measures: The secondary attack rate and infectious viral shedding kinetics according to COVID-19 vaccination status.

Results: A total of 173 individuals (median [IQR] age, 47 [32-59] years; 100 female [58%]) with COVID-19 were included in the secondary transmission study, of whom 50 (29%) had a breakthrough infection. Secondary transmission was significantly less common in the breakthrough infection group than in the nonbreakthrough infection group (3 of 43 [7%] vs 29 of 110 [26%]; P = .008). In the viral shedding kinetics study, 45 patients (median age, 37 years [IQR, 25-49 years]; 14 female [31%]) infected with the Delta variant were included, of whom 6 (13%) were fully vaccinated and 39 (87%) were partially or unvaccinated. Although the initial genomic viral load was comparable between the 2 groups, viable virus in cell culture was detected for a notably longer duration in partially vaccinated (8 days after symptom onset) or unvaccinated (10 days after symptom onset) individuals compared with fully vaccinated individuals (4 days after symptom onset).

Conclusions And Relevance: In this cohort study, although the initial genomic viral load was similar between vaccinated and unvaccinated individuals, fully vaccinated individuals had a shorter duration of viable viral shedding and a lower secondary attack rate than partially vaccinated or unvaccinated individuals. Data from this study provide important evidence that despite the possibility of breakthrough infections, COVID-19 vaccinations remain critically useful for controlling the spread of SARS-CoV-2.

Citing Articles

Adjuvanted subunit intranasal vaccine reduces SARS-CoV-2 onward transmission in hamsters.

Sui Y, Kar S, Chawla B, Hoang T, Yu Y, Wallace S Front Immunol. 2025; 16:1514845.

PMID: 39981227 PMC: 11841495. DOI: 10.3389/fimmu.2025.1514845.


Strength and durability of indirect protection against SARS-CoV-2 infection through vaccine and infection-acquired immunity.

Tan S, Rodriguez-Barraquer I, Kwan A, Blumberg S, Park H, Hutchinson J Nat Commun. 2025; 16(1):1090.

PMID: 39881133 PMC: 11779853. DOI: 10.1038/s41467-024-55029-9.


Passive infusion of an S2-Stem broadly neutralizing antibody protects against SARS-CoV-2 infection and lower airway inflammation in rhesus macaques.

Edwards C, Karunakaran K, Garcia E, Beutler N, Gagne M, Golden N PLoS Pathog. 2025; 21(1):e1012456.

PMID: 39847599 PMC: 11793774. DOI: 10.1371/journal.ppat.1012456.


Relationship Between Acute SARS-CoV-2 Viral Clearance and Long COVID-19 (Long COVID) Symptoms: A Cohort Study.

Herbert C, Antar A, Broach J, Wright C, Stamegna P, Luzuriaga K Clin Infect Dis. 2024; 80(1):82-90.

PMID: 39692474 PMC: 11797388. DOI: 10.1093/cid/ciae539.


High protection and transmission-blocking immunity elicited by single-cycle SARS-CoV-2 vaccine in hamsters.

Lett M, Otte F, Hauser D, Schon J, Kipfer E, Hoffmann D NPJ Vaccines. 2024; 9(1):206.

PMID: 39472701 PMC: 11522273. DOI: 10.1038/s41541-024-00992-z.


References
1.
Harris R, Hall J, Zaidi A, Andrews N, Dunbar J, Dabrera G . Effect of Vaccination on Household Transmission of SARS-CoV-2 in England. N Engl J Med. 2021; 385(8):759-760. PMC: 8262621. DOI: 10.1056/NEJMc2107717. View

2.
Singanayagam A, Hakki S, Dunning J, Madon K, Crone M, Koycheva A . Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study. Lancet Infect Dis. 2021; 22(2):183-195. PMC: 8554486. DOI: 10.1016/S1473-3099(21)00648-4. View

3.
Del Rio C, Malani P, Omer S . Confronting the Delta Variant of SARS-CoV-2, Summer 2021. JAMA. 2021; 326(11):1001-1002. DOI: 10.1001/jama.2021.14811. View

4.
Congrave-Wilson Z, Lee Y, Jumarang J, Perez S, Bender J, Bard J . Change in Saliva RT-PCR Sensitivity Over the Course of SARS-CoV-2 Infection. JAMA. 2021; 326(11):1065-1067. PMC: 8456387. DOI: 10.1001/jama.2021.13967. View

5.
Savela E, Viloria Winnett A, Romano A, Porter M, Shelby N, Akana R . Quantitative SARS-CoV-2 Viral-Load Curves in Paired Saliva Samples and Nasal Swabs Inform Appropriate Respiratory Sampling Site and Analytical Test Sensitivity Required for Earliest Viral Detection. J Clin Microbiol. 2021; 60(2):e0178521. PMC: 8849374. DOI: 10.1128/JCM.01785-21. View